Introduction {#S1}
============

Breast cancer (BC) is the most common cancer type in women; its mortality is mostly due to distant metastatic growth. The phenomenon of hematogenous spread of single tumor cells shed from the primary tumor was first demonstrated in nineteenth century ([@B1], [@B2]). Tumor cells encountered at secondary homing sites, such as bone marrow (BM) and peripheral blood (PB), are currently seen as surrogate marker for minimal residual disease (MRD) and precursors of distant metastasis. Detection of these cells and evaluation of their features can therefore contribute to our better understanding of the disease and improve therapy monitoring as well as personalized treatment options. The features of tumor cells and changes in the microenvironment at the homing site are the major subject of current translational research.

The prognostic significance of MRD in BC was first demonstrated in studies on disseminated tumor cells (DTCs) in BM. In 2005, a multicenter meta-analysis of BM aspirates collected from 4703 non-metastatic BC patients at time of diagnosis confirmed that DTC presence significantly correlates with shorter disease-free survival (DFS) and overall survival ([@B3]). Since venipuncture is more feasible than BM aspiration, subsequent studies shifted their focus to the easily accessible circulating tumor cells (CTCs) in the PB. The following review will address the current knowledge and future clinical possibilities of CTC evaluation in BC.

Circulating Tumor Cells in Early Breast Cancer {#S2}
==============================================

The metastatic cascade consists of a series of steps that enable cells from the primary tumor to enter blood vessels, persist in initially hostile homing sites, and finally extravasate into the tissue of secondary organs. These steps may take place over a prolonged period of time, sometimes decades, involving mechanisms known as tumor cell dormancy ([@B4]). Due to improved screening, the majority of BC patients presents with disease localized to the breast and lymph nodes without evidence of distant metastasis. However, after completion of surgical treatment and adequate adjuvant therapy, a significant proportion of patients suffer from a distant recurrence, suggesting that the metastatic cascade had already been activated long before diagnosis.

Accumulating evidence suggests that the fate of tumor cells detached from the primary tumor is highly influenced not only by their own properties but also by microenvironment and immune system. In the blood stream and later in BM and distant organs, these rare cells are exposed to immune response of the host. It is widely accepted that a significant proportion of CTCs dies leaving only a small subpopulation capable of persistence, in a process generally referred to as "metastatic inefficiency" ([@B5]). Due to the rapid clearance of CTCs from the blood stream mediated by macrophages, monocytes, neutrophils, and natural killer cells, MRD is under continuous survival pressure to develop mechanisms enabling immune escape ([@B6]). Indeed, CTCs have been shown to overexpress proteins inhibiting the phagocytic activity of immune cells and downregulate major histocompatibility class I antigen expression ([@B7]--[@B10]). It has also been suggested that CTCs are able to stimulate the formation of premetastatic niche in secondary organs. In this context, a number of possible mechanisms have been proposed. Through expression of vascular signal proteins, CTCs can attract VEGFR-expressing hematopoetic stem cells that influence fibroblasts at the homing site, thus creating a favorable microenvironment for future metastatic growth ([@B11]). In an animal BC model, tumor cells were shown to induce production of chemokine ligands, especially CCL17 and CCL22, at secondary sites, leading to chemotaxis of both tumor and immune cells. A better knowledge of interactions between CTCs, the immune system and microenvironment could provide us with new therapeutic targets ([@B12]).

Prognostic Significance of CTCs in Early BC {#S2-1}
-------------------------------------------

Non-metastatic BC patients in whom tumor cells spread into the blood stream, i.e., who present with CTCs in their PB, are more likely to relapse in the course of disease (Table [1](#T1){ref-type="table"}). To date, the largest clinical trial on the prognostic relevance of CTCs in early BC was launched by the German SUCCESS study group (EUDRA-CT No. 2005-000490-21, NCT02181101). Briefly, blood samples from over 2000 average-to-high-risk non-metastatic BC patients before chemotherapy and nearly 1500 patients after chemotherapy were examined ([@B13]). Women with detectable CTCs before chemotherapy had significantly worse DFS and overall survival. In this trial, the relationship between CTC numbers and survival was evaluated in order to determine the optimal cutoff (no CTCs vs. ≥1; 0--1 vs. ≥2; 0--4 vs. ≥5 CTCs in 30 ml blood). For all cutoffs, a statistically significant impact on survival was shown. Women with five and more CTCs had highest risk for relapse. So far, the results from the SUCCESS trial were reported after a median follow-up of 36 months. Smaller trials with longer follow-up demonstrated the association between CTC presence and clinical outcome as well ([@B14], [@B15]). In a multicenter pooled analysis, Janni et al. confirmed CTC presence in early BC patients as an independent predictor of shorter disease-free, overall, BC-specific, and distant DFS ([@B16]). In the multivariate analysis, for all four survival endpoints alike, grading, tumor stage, nodal stage, hormone receptor status, and HER2 status were additional significant independent prognostic factors, while histologic type, menopausal status, neoadjuvant chemotherapy, and adjuvant chemotherapy were not significantly associated with disease recurrence or survival. Beyond that, the analysis added important new data on the prognostic value of CTCs in various BC subgroups. Most importantly, CTC presence did not significantly influence clinical outcome in low-risk patients with small node-negative tumors, suggesting that early-stage BCs could be treated successfully, independently of the presence of MRD in the blood. In contrast, the strong prognostic value of CTCs in high-risk patients underlines the future potential of CTCs to drive treatment decisions in this patient group. Furthermore, Janni et al. evaluated CTC detection in different molecular subgroups. Hypothetically, tumor cell dissemination patterns may differ according to the biological features of the disease. Indeed, CTC presence predicted survival in patients with tumors of the luminal subtype (i.e., hormone receptor-positive, including luminal B HER2-positive subtype) and with triple-negative tumors, but not in patients with HER2-positive, hormone receptor-negative tumors ([@B16]). Contrary to these results, Ignatiadis et al. found in a smaller study no association between CTC presence and prognosis in patients with luminal tumors, while CTC status was highly predictive of survival in the triple-negative and HER2-subtype ([@B17], [@B18]). Similar findings were reported by others ([@B19]--[@B21]). One aspect that needs to be taken into account is a relatively short follow-up of the available studies; so far, none of the abovementioned trials reported a follow-up longer than 100 months. Especially in case of hormone receptor-positive BC, this might be insufficient to fully assess the clinical relevance of CTC presence as patients with luminal tumors are more at risk for a late relapse compared to those with more aggressive tumor subtypes ([@B22]).

###### 

**Presence of CTCs and clinical outcome in non-metastatic BC patients**.

  Reference                                                                Patients                                                                                                   Number of patients   CTC positivity   Method                                      Median follow-up (months)   Association between CTCs and survival
  ------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------- -------------------- ---------------- ------------------------------------------- --------------------------- ---------------------------------------
  Janni et al. ([@B16]) pooled analysis[^a^](#tfn1){ref-type="table-fn"}   Stages I--III                                                                                              3173                 641 (20%)        CellSearch                                  63                          DFS, DDFS, BCSS, OS
  Rack et al. ([@B13]), SUCCESS trial                                      Stages I--III, node-positive or high-risk node-negative, all pts. received chemotherapy                    2026                 435 (21%)        CellSearch                                  36                          DFS, DDFS, BCSS, OS
  Franken et al. ([@B15])                                                  Stages I--III                                                                                              404                  76 (19%)         CellSearch                                  48                          DDFS, BCSS
  Lucci et al. ([@B23])                                                    Stages I--III                                                                                              302                  73 (24%)         CellSearch                                  35                          DFS, OS
  Bidard et al. ([@B14]), REMAGUS02 trial                                  Neoadjuvant trial, Stages II and III, ineligible for breast conserving surgery at diagnosis or high-risk   95                   22 (23%)         CellSearch                                  70                          DDFS, OS
  Molloy et al. ([@B24])                                                   Stages I and II                                                                                            733                  58 (8%)          qRT-PCR (CK19, p1B, EGP-2, PS2, and MmGI)   91                          MFS, BCSS
  Ignatiadis et al. ([@B17])                                               Stages I--III, all pts. received adjuvant chemotherapy                                                     444                  181 (41%)        RT-PCR (CK19)                               54                          DFS, OS
  Kuniyoshi et al. ([@B25])                                                Stages I--III                                                                                              167                                   RT-PCR (CK19, c-erbB-2)                                                 n.s.
  Hwang et al. ([@B19])                                                    Stages I--IIIa                                                                                             166                  37 (22%)         RT-PCR (CK20)                               100                         MFS, OS

*n.s., not significant; BCSS, breast cancer-specific survival; DDFS, distant disease-free survival; DFS, disease-free survival; OS, overall survival; MFS, metastasis-free survival*.

*^a^Pooled analysis including data from five centers, some previously published as Ref. ([@B13], [@B14], [@B15], [@B23])*.

The ability to assess tumor subtypes has been one of the mile stones toward personalized oncological treatment. In this context, considerable efforts have been undertaken to characterize the phenotype of CTCs and explore potential clinical applications beyond mere enumeration of tumor cells. It has been shown that expression profiles of CTCs do not correlate with the subtype of the corresponding primary tumor ([@B26]). However, while the presence of CTCs has been confirmed as an important predictor of worse survival in large trials, evidence regarding prognostic relevance of specific subtypes of CTCs in early BC is scarce. Wulfing et al. assessed the HER2 status of CTCs in a small cohort of 35 stages I--III BC patients and reported a significant association between positive HER2 status and shorter DFS and overall survival ([@B27]).

The relationship between DTCs in BM and CTCs in PB has been explored in a number of studies. While both DTCs and CTCs have been shown to predict clinical outcome with level I evidence ([@B3], [@B16]), only a few studies assessed both markers in patients with primary BC. The correlation between CTC and DTC positivity seems weak, ranging from 55 to 76%, depending on the patient population and the method used ([@B28]--[@B31]). Which "homing site" is better suited for survival prediction remains unclear; while several studies found a stronger correlation between DTC presence and clinical outcome, others provided results in favor of CTCs. The major advantage of blood-based detection is the simplicity of blood sampling in comparison to BM biopsy. Since the procedure is non-invasive, serial measurements are possible.

CTCs as a Therapy Monitoring Tool in Early BC {#S2-2}
---------------------------------------------

Breast cancer patients in whom MRD in the BM persist beyond adjuvant chemotherapy are more likely to be diagnosed with a subsequent relapse ([@B32]). Evidence from CTC-based clinical trials showed that persistence of CTCs in the blood is associated with worse clinical outcome as well (Table [2](#T2){ref-type="table"}). The SUCCESS trial demonstrated that CTC persistence correlates with shorter recurrence-free and overall survival ([@B13]). When both prechemotherapy and postchemotherapy CTC status was considered, the 36-month OS and DFS were higher in patients who were CTC-negative at both time points compared to those CTC-positive before and after chemotherapy (OS: 97.6 vs. 92.8%; DFS: 93.9 vs. 85.9%, respectively). Furthermore, presence of persistent CTCs 2 years after completion of chemotherapy in clinically disease-free patients predicted worse survival as well ([@B33]). In this context, one needs to keep in mind that CTCs represent a heterogenous population and that while systemic treatment may eradicate a large proportion of CTCs, tumor cells with enhanced resistant mechanisms may survive and lead to metastatic growth. To date, however, evidence regarding clinical relevance of specific subtypes of persistent CTCs is limited.

###### 

**Presence of persistent CTCs and clinical outcome in non-metastatic BC patients**.

  Reference                                                        Patient collective                                                                                                                                                               Number of patients   CTC positivity   Method       Median follow-up (months)   Association between CTCs and survival   Association between CTCs and pathological response of the primary tumor to neoadjuvant therapy
  ---------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ---------------- ------------ --------------------------- --------------------------------------- ------------------------------------------------------------------------------------------------
  Rack et al. ([@B13]), SUCCESS trial                              Stages I--III, node-positive or high risk node-negative; blood sample taken after adjuvant chemotherapy                                                                          1493                 330 (22%)        CellSearch   36                          DFS, OS                                 --
  Riethdorf et al. ([@B34]), GeparQuattro trial                    High-risk non-metastatic BC after neoadjuvant chemotherapy                                                                                                                       207                  22 (11%)         CellSearch   --                          n.d.                                    No
  Kasimir-Bauer et al. ([@B35])                                    Neoadjuvant trial, Stages II and III, ineligible for breast conserving surgery at diagnosis or high-risk; blood and BM samples taken before and after neoadjuvant chemotherapy   133                  11 (8%)          AdnaTest     52                          No                                      No
  Hall et al. ([@B36])                                             Triple-negative early BC after neoadjuvant chemotherapy                                                                                                                          57                   17 (30%)         CellSearch   30                          RFS, OS                                 No
  Bidard et al. ([@B14]), Pierga et al. ([@B37]) REMAGUS02 trial   Neoadjuvant trial, Stages II and III, ineligible for breast conserving surgery at diagnosis or high-risk; blood sample taken after neoadjuvant chemotherapy                      85                   15 (18%)         CellSearch   70                          No                                      No

*DFS, disease-free survival; OS, overall survival; RFS, relapse-free survival*.

Furthermore, Hall et al. examined blood samples from 57 patients with triple-negative BC after completion of neoadjuvant therapy and found a significant correlation between CTC presence and shorter relapse-free and overall survival ([@B36]). Others reported conflicting results in the neoadjuvant setting ([@B14], [@B35], [@B38]). Several studies aimed at exploring the interaction between CTC dynamics and pathological changes in the primary tumor during chemotherapy. Pathological complete response has been shown to predict long-term survival and is being used as an endpoint in numerous clinical trials ([@B39]). However, changes in CTCs were not associated with tumor's response to treatment in most studies; in the neoadjuvant REMAGUS02 trial, neither presence of persistent CTCs after chemotherapy nor changes in CTC status correlated with pathological complete response ([@B37]). Riethdorf et al. examined blood samples from 213 BC patients before and 207 BC patients after neoadjuvant treatment in the GeparQuattro trial ([@B34]). While CTCs could be detected in 22% of patients before start of treatment, the positivity rate decreased to 11% after chemotherapy. However, no correlation between response to therapy and CTC dynamics could be found.

In the neoadjuvant setting, achievement of pathological complete response is significantly linked to favorable survival. In case of adjuvant therapy, this simple tool for response monitoring is no longer available as systemic treatment is administered after surgery. In a study by Xenidis et al., 237 initially CTC-positive patients received either taxane-based or taxane-free adjuvant therapy ([@B40]). After a median follow-up of 71 months, patients treated with taxane-based regimen had longer DFS than those receiving taxane-free treatment. Positive effects on survival in the taxane-group were reflected by a shift toward CTC-negative status: 50% of taxane-treated patients turned CTC-negative compared to only 33% in the taxane-free arm.

Therapy Choices Based on CTCs in Early BC {#S2-3}
-----------------------------------------

Treatment decisions in non-metastatic BC are based on the characteristics of the primary tumor without considering features of MRD, although the latter is the aim of any adjuvant strategy and molecular profile of MRD may differ from the primary tumor ([@B41]). For instance, we previously reported that 71% of patients with ER-positive BC present with ER-negative DTCs in BM; the loss of hormone receptor positivity may contribute to development of endocrine resistance ([@B42]). With regard to another predictive marker, HER2, Riethdorf et al. demonstrated that in 19% of patients with HER2-negative BC HER2-positive CTCs may be detected in PB ([@B34]). Similar results were reported with respect to DTCs in BM as well ([@B26], [@B34], [@B43]). According to current guidelines, patients with HER2-positive MRD but HER2-negative tumors are not eligible for anti-HER2-targeted treatment since only histologically proven HER2 status -- either in the primary tumor or in a metastatic lesion -- is taken into account. Whether this undertreatment results in worse survival and, consequently, whether these patients benefit from HER2-targeted therapy, remains to be clarified. Rack et al. showed that secondary adjuvant administration of trastuzumab eliminates HER2-positive DTCs from the BM of patients with HER2-negative BC ([@B44]). The ongoing TREAT CTC trial (NCT01548677) is the first liquid biopsy-based large trial evaluating the concept of targeting chemoresistant MRD ([@B45]). Patients with CTCs persisting beyond (neo)adjuvant chemotherapy are randomized between six cycles of trastuzumab intravenously every 3 weeks vs. observation. In this trial, HER2 status of the CTCs will be assessed, but the treatment is based on the presence of CTCs and not on their HER2 status. Apart from the patients' characteristics of the pilot phase, this trial has not reported any results yet.

Circulating Tumor Cells in Metastatic Breast Cancer {#S3}
===================================================

Prognostic Significance of CTCs in Metastatic BC {#S3-1}
------------------------------------------------

A total of 40--80% of patients with metastatic BC present with CTCs in PB (Table [3](#T3){ref-type="table"}). As demonstrated by Cristofanilli et al., CTC levels above the cutoff value of ≥5 cells/7.5 ml blood at the time of diagnosis are associated with impaired clinical outcome ([@B46], [@B47]). The prognostic value of the threshold of ≥5 CTCs/7.5 ml PB has been further validated by several studies and remains unchanged during the follow-up ([@B37], [@B47]--[@B52]). A recent pooled analysis on 1944 metastatic BC patients demonstrated the influence of CTCs on progression-free and overall survival with the highest level of evidence ([@B53]).

###### 

**Prognostic value of CTCs in metastatic breast cancer patients**.

  Reference                       Number of patients   Method                CTC positivity                                      Association between CTCs and survival
  ------------------------------- -------------------- --------------------- --------------------------------------------------- ------------------------------------------
  Bidard et al. ([@B53])          1944                 CellSearch            47%[^a^](#tfn2){ref-type="table-fn"}                PFS, OS
  Smerage et al. ([@B54])         564                  CellSearch            51%[^a^](#tfn2){ref-type="table-fn"}                PFS, OS
  Wallwiener et al. ([@B52])      486                  CellSearch            42%                                                 PFS, OS
  Giordano et al. ([@B51])        517                  CellSearch            40%[^a^](#tfn2){ref-type="table-fn"}                PFS, OS
  Pierga et al. ([@B55])          267                  CellSearch            44%[^a^](#tfn2){ref-type="table-fn"}                PFS, OS
  Müller et al. ([@B56])          254                  CellSearch AdnaTest   CSS: 50%[^a^](#tfn2){ref-type="table-fn"} AT: 40%   CellSearch: OS AdnaTest: n.s.
  Giuliano et al. ([@B50])        235                  CellSearch            40%[^a^](#tfn2){ref-type="table-fn"}                PFS, OS
  Nakamura et al. ([@B57])        107                  CellSearch            37%[^a^](#tfn2){ref-type="table-fn"}                PFS
  Liu et al. ([@B58])             74                   CellSearch            n.s.                                                PFS
  Tewes et al. ([@B59])           42                   AdnaTest              52%                                                 OS
  Bidard et al. ([@B60])          37                   Immunocytochemistry   41%                                                 OS
  Nole et al. ([@B61])            80                   CellSearch            61%                                                 PFS
  Hayes et al. ([@B49])           177                  CellSearch            54%                                                 PFS, OS[^b^](#tfn3){ref-type="table-fn"}
  Budd et al. ([@B48])            138                  CellSearch            43%                                                 OS
  Cristofanilli et al. ([@B47])   177                  CellSearch            49%                                                 PFS, OS

*PFS, progression-free survival; OS, overall survival*.

*^a^≥5 CTCs*.

*^b^At any time during palliative treatment*.

Next to the prognostic role of CTC status, changes in CTC counts in course of treatment have been shown to reflect therapy response: in the analysis by Hayes et al., a decrease in CTC levels under the threshold of five cells in 7.5 ml PB predicted better PFS and OS ([@B49]). Furthermore, treatment efficacy assessed by CTC evaluation might be more suitable for therapy monitoring than standard radiological imaging ([@B48]). In a prospective trial by Budd et al., CTC persistence in metastatic BC patients predicted impaired clinical outcome despite radiological therapy response ([@B48]). In this context, a simple and non-invasive blood analysis for CTCs as a "liquid biopsy" represents an attractive tool allowing a real-time monitoring of disease progression and therapy response.

Beyond CTC enumeration and monitoring of CTC levels during the therapy, characterization of these cells, especially with regard to hormone and HER2 status, has been addressed in several studies on metastatic BC. According to numerous trials, the phenotype and genotype of primary tumor, metastatic lesion, and CTCs often differ ([@B62]--[@B66]). Hypothetically, CTCs represent the dominant tumor cell population in metastatic disease; therefore, their expression profile may predict therapeutic response most adequately ([@B67]). As reported to date, targeted therapy guided by phenotype of CTCs is able to eliminate persistent tumor cells from PB and/or BM of BC patients ([@B44], [@B68], [@B69]). While prognostic relevance of CTC enumeration in the metastatic setting has been proven in large clinical trials, studies investigating the impact of specific phenotypes of CTCs on survival have yielded contradictory results. Wallwiener et al. evaluated HER2 status on CTCs in 107 metastatic BC patients starting a new line of therapy ([@B65]). The HER2 status of CTCs did not influence overall survival. However, patients with HER2-positive CTCs had significantly longer PFS than those with HER2-negative CTCs. In contrast, Hayashi et al. reported worse survival in patients with HER2-positive CTCs ([@B70]), and Beije et al. assessed ER and HER2 status on CTCs from 154 MBC patients and reported that none correlated with clinical outcome ([@B71]).

Clinical significance of CTC phenotype (in particular, the HER2 status) for guiding treatment decisions and evaluating therapy response in metastatic BC is being currently investigated within the German DETECT trials (NCT01619111). Moreover, the possibility to provide an analysis of CTCs in metastatic BC on a DNA, RNA, and protein level including next-generation sequencing has been demonstrated by recent research ([@B72], [@B73]). CTC characterization on the molecular level might help to identify resistance mechanisms of tumor cells: a crucial step for the optimization of systemic treatment ([@B67]).

CTCs as a Therapy Monitoring Tool in Metastatic BC {#S3-2}
--------------------------------------------------

While the prognostic relevance of CTC detection has been proven in large clinical trials, its clinical utility remains to be demonstrated ([@B13], [@B47]). Since CTC detection predicts impaired clinical outcome and CTC dynamics seem to reflect treatment response, a question has been raised, whether MBC patients can benefit from CTC-guided therapy decisions. The first large clinical trial to address this issue is the SWOG S0500 study (NCT00382018). In this randomized Phase III trial, metastatic BC patients with persistent high levels of CTCs after first cycle of initial chemotherapy (≥5/7.5 ml of blood) were randomized to switch the therapy or to maintain the current treatment until the clinical evidence of progression ([@B54]). While the strong prognostic power of CTCs has been confirmed by this study, treatment change based on CTC persistence did not improve progression-free survival or overall survival in these patients. The clinical outcome was poorest in patients with persistently elevated CTC levels, and these patients might represent a chemoresistant population that requires alternative treatment approaches ([@B54]). Furthermore, a currently ongoing study on therapy guidance based on CTC dynamics in metastatic BC is the CirCe01 by Institut Curie, France (NCT01349842). In this multicentre randomized Phase III study, therapy response in CTC-positive patients with disease progression after two lines of chemotherapy is being assessed by clinical tests and radiological imaging or by CTC enumeration. Patients without a significant decrease in CTC levels after first cycle of new chemotherapy will be switched to an alternative regime, which will also be evaluated by CTCs. First results of CirCe01 are expected in 2018 ([@B74]). Both studies attempt to demonstrate that patients with persistently elevated CTCs under cytotoxic treatment should be switched off this regimen early in order to avoid inefficient and toxic chemotherapies.

Therapy Choices Based on CTCs in Metastatic BC {#S3-3}
----------------------------------------------

The question whether the choice of systemic treatment in hormone receptor-positive HER2-negative metastatic BC patients might be driven by CTC levels has been raised by the STIC-CTC trial (NCT01710605, Institut Curie, France). In this randomized Phase III trial, the treatment decision will be left at the discretion of the clinicians or according to the number of CTCs in PB: endocrine therapy in case of a CTC count \<5 CTCs/7.5 ml PB or chemotherapy in case of a CTC count ≥5/7.5 ml PB.

The worldwide largest trial for therapy guidance according to the CTC status and/or CTC phenotype in metastatic BC patients is the DETECT study concept. In this multicenter study, women with HER2-negative metastatic disease and at least one HER2-positive CTC are enrolled in the DETECT III trial (NCT01619111), and women with HER2-negative BC (hormone receptor-positive or triple-negative) and exclusively HER2-negative CTCs are eligible for the DETECT IV trial (NCT02035813). The recently initiated DETECT V/CHEVENDO trial (Chemo vs. Endo, NCT02344472) completes the DETECT study program with a clinical trial for HER2-positive hormone receptor-positive metastatic BC patients. In the DETECT III trial, patients are randomized to standard systemic treatment of physician's choice ± additional therapy with lapatinib. In the DETECT IV trial, patients with hormone receptor-positive tumors are treated with endocrine therapy plus everolimus, as a study medication, whereas patients with hormone receptor-positive tumors and indication for chemotherapy as well as patients with triple-negative tumors are treated with eribulin. Metastatic BC patients with HER2-positive hormone receptor-positive tumors are treated with dual HER2-targeted therapy (pertuzumab/trastuzumab) either in combination with chemotherapy or endocrine therapy within the DETECT V/CHEVENDO trial. In DETECT III and DETECT IV, presence of CTCs is mandatory for study inclusion and changes in CTC levels during the treatment are evaluated by repeated blood sampling during the therapy. The accompanying translational research projects of all DETECT studies try to generate additional knowledge of CTCs, their biology and their role in predicting treatment response using methods like single cell analysis, SNaP-Shot technology and next-generation sequencing. This may help to identify new treatment targets and provide more individualized therapy and finally further clarify the clinical value of CTCs in metastatic BC. Currently, ongoing trials on therapeutic utility of CTCs in metastatic BC are summarized in Table [4](#T4){ref-type="table"}.

###### 

**Current studies on therapeutic utility of CTCs in metastatic breast cancer**.

  Trial                                  Status                   Condition                                             Intervention                                                                                   Primary endpoint
  -------------------------------------- ------------------------ ----------------------------------------------------- ---------------------------------------------------------------------------------------------- ---------------------
  SWOG S0500 *NCT00382018* (Phase III)   Active, not recruiting   CTC persistence under chemotherapy                    Treatment choice based on clinical and radiological criteria vs. CTC-guided treatment choice   OS
  CirCe01 *NCT01349842* (Phase III)      Recruiting               CTC persistence under chemotherapy                    Treatment choice based on clinical and radiological criteria vs. CTC-guided treatment choice   OS
  STIC-CTC *NCT01710605* (Phase III)     Recruiting               HR+/HER2− MBC                                         Clinicians choice vs. CTC-guided choice between chemotherapy and endocrine therapy             PFS
  DETECT III *NCT01619111* (Phase III)   Recruiting               HER2-negative metastatic BC with HER2-positive CTCs   Standard therapy ± lapatinib                                                                   CTC clearance
  DETECT IV *NCT02035813* (Phase II)     Recruiting               HER2-negative metastatic BC with HER2-negative CTCs   Endocrine therapy + everolimus (DETECT IV a) or eribulin (DETECT IV b)                         PFS
  *NCT01975142* (Phase II)               Recruiting               HER2-negative metastatic BC with HER2-positive CTCs   T-DM1                                                                                          Tumor response rate

Conclusion {#S4}
==========

Evaluation of CTCs is one of the most promising biomarkers in solid tumors. In BC, presence of CTCs is an independent predictor of poor clinical outcome in both early and metastatic setting. Numerous potential clinical applications have been proposed and are currently being investigated (Table [5](#T5){ref-type="table"}). In case of early BC, the assessment of therapeutic targets is so far restricted to the primary tumor despite increasing evidence of significant discordances between primary tumor and MRD, especially with respect to hormone receptor and HER2 status. Since CTCs might reflect certain, hypothetically most aggressive, subpopulations of the tumor, molecular analysis of these cells and detection of their persistence might identify patients in need of additional or targeted treatment.

###### 

**Potential future applications of CTC detection and characterization**.

  Early BC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Metastatic BC
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CTC detection might improve prognostication and help to identify patients in need of aggressive therapy and/or bisphosphonatesCTC persistence might serve as stratifying parameter to select patients who benefit most from extended endocrine treatmentPatients with CTC persistence beyond adjuvant chemotherapy might potentially benefit from secondary adjuvant treatmentEvaluation of predictive markers on CTCs might serve as basis for treatment decisions: e.g., patients with HER2-negative primary tumor but HER2-positive CTCs might benefit from HER2-targeted therapy   Detection of high CTC levels and thus worse prognosis might become a valuable information for improved care planning in palliative settingCTC detection after start of a new line of chemotherapy helps to predict response to treatment early; patients with high CTC levels might either be switched to another therapy approach (benefit so far not confirmed in trials) or to best supportive care to avoid unnecessary toxicityEvaluation of CTCs may serve as a liquid biopsy and thus render invasive biopsy of metastasis unnecessary; serial CTC measurements might provide continuous insight into current status of the disease

In metastatic disease, one of the most exciting possibilities is the concept of CTC-guided treatment. Two settings are currently under investigation: first, since several studies have shown that persistently high CTC levels under systemic therapy reflect disease progression sooner than imaging-based monitoring, CTC monitoring might help to identify patients who do not benefit from cytotoxic treatment. However, since an early switch to another chemotherapy regimen in case of high CTC levels after the first cycle of palliative treatment has not shown any survival benefit, it remains to be clarified which therapy options should be favored in such case. Second, a number of clinical trials aim at clarifying whether metastasized patients benefit from targeted therapy based on the molecular profile of CTCs rather than that of the primary tumor.
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